SCHEMBL5887121

SCHEMBL5887121

Cc1nc(N2CCN(c3ccccn3)CC2)nc2c1ccc(=O)n2-c1ccc(C(=O)OC(C)(C)C)cc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.41
KDM4E B2RXH2 4/20 0.40
ALDH1A1 P00352 4/20 0.40
MAPT P10636 2/20 0.40
HSD17B10 Q99714 2/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
HSP90AA1 P07900 1/20 0.37
HSP90AB1 P08238 1/20 0.37
LMNA P02545 1/20 0.37
TSHR P16473 1/20 0.37
CTNNB1 P35222 1/20 0.37
TCF7L2 Q9NQB0 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887125 0.92 RAB9A (0.42) GPR119ALDH1A1MAPTHSD17B10MAPK1
SCHEMBL5886809 0.89 ALDH1A1 (0.41) GPR119ALDH1A1MAPTHSD17B10HTT
SCHEMBL5886849 0.88 KDM4E (0.43) KDM4EALDH1A1MAPTHSD17B10MAPK1
SCHEMBL5886783 0.87 CHEK2 (0.44) KDM4EALDH1A1MAPTHSD17B10MAPK1
SCHEMBL5886843 0.87 KDM4E (0.43) KDM4EALDH1A1MAPTHSD17B10MAPK1
SCHEMBL5886717 0.84 MEN1 (0.40) KDM4EALDH1A1MAPTMAPK1MEN1
SCHEMBL5887120 0.83 CTNNB1 (0.44) KDM4EALDH1A1MAPTHSD17B10MAPK1
SCHEMBL5887071 0.82 DRD2 (0.48) KDM4EALDH1A1SMN1; SMN2LMNACTNNB1
SCHEMBL5886729 0.82 ALDH1A1 (0.37) KDM4EALDH1A1
SCHEMBL5887267 0.81 CTNNB1 (0.45) KDM4EALDH1A1MAPTHSD17B10MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US claimed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US claimed
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US disclosed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors TERT, TERF2, TERF2IP GPR119 4543/4885KDM4E 840/4885ALDH1A1 1860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.